| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JNS.2009.02.326 |
| P8608 | Fatcat ID | release_4ros73bvnbfpdi5vcsbzd2abwu |
| P698 | PubMed publication ID | 19268309 |
| P50 | author | Laszlo Vecsei | Q1462365 |
| Peter Klivenyi | Q61010043 | ||
| József Toldi | Q96054878 | ||
| P2093 | author name string | Arpad Pardutz | |
| Eniko Vamos | |||
| P433 | issue | 1-2 | |
| P921 | main subject | nervous system | Q9404 |
| P304 | page(s) | 21-27 | |
| P577 | publication date | 2009-03-05 | |
| P1433 | published in | Journal of the Neurological Sciences | Q6296168 |
| P1476 | title | The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection | |
| P478 | volume | 283 |
| Q48710057 | 16p11.2 600 kb Duplications confer risk for typical and atypical Rolandic epilepsy. |
| Q52571058 | A Three-Ring Circus: Metabolism of the Three Proteogenic Aromatic Amino Acids and Their Role in the Health of Plants and Animals. |
| Q34585754 | A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function |
| Q48720140 | A novel kynurenic acid analog (SZR104) inhibits pentylenetetrazole-induced epileptiform seizures. An electrophysiological study : special issue related to kynurenine. |
| Q44511847 | ACTH protects mature oligodendroglia from excitotoxic and inflammation-related damage in vitro |
| Q48961949 | Behavioural studies with a newly developed neuroprotective KYNA-amide. |
| Q38029716 | Biomarkers for attention-deficit/hyperactivity disorder (ADHD). A consensus report of the WFSBP task force on biological markers and the World Federation of ADHD. |
| Q34101885 | Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial |
| Q36593081 | Branched-chain amino acids alter neurobehavioral function in rats |
| Q38179453 | Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs. |
| Q26740330 | Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis |
| Q37876426 | Current strategies in the discovery of small-molecule biomarkers for Alzheimer's disease |
| Q58050566 | Detection of Genomic Imbalances by Array-Based Comparative Genomic Hybridization in Bulgarian Patients with Autism Spectrum Disorders |
| Q60732919 | Different inhibitory effects of kynurenic acid and a novel kynurenic acid analogue on tumour necrosis factor-α (TNF-α) production by mononuclear cells, HMGB1 production by monocytes and HNP1-3 secretion by neutrophils |
| Q89719841 | Discovery of Kynurenines Containing Oligopeptides as Potent Opioid Receptor Agonists |
| Q51907611 | Duplication 16p11.2 in a child with infantile seizure disorder. |
| Q34090453 | Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression |
| Q46932015 | Effects of dextromethorphan on glial cell function: proliferation, maturation, and protection from cytotoxic molecules |
| Q90680244 | Effects of the Novel IDO Inhibitor DWG-1036 on the Behavior of Male and Female 3xTg-AD Mice |
| Q40924999 | Gas chromatography/tandem mass spectrometry detection of extracellular kynurenine and related metabolites in normal and lesioned rat brain |
| Q35749186 | Gene expression during zombie ant biting behavior reflects the complexity underlying fungal parasitic behavioral manipulation |
| Q61807984 | Gut Microbiota Dysbiosis Is Not Independently Associated With Neurocognitive Impairment in People Living With HIV |
| Q53408140 | Human kynurenine aminotransferase II - reactivity with substrates and inhibitors |
| Q43207575 | In vivo neuroprotective effects of peripheral kynurenine on acute neurotoxicity induced by glutamate in rat cerebral cortex |
| Q24635451 | Inflammation in depression: is adiposity a cause? |
| Q33832055 | Interferon-γ regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). |
| Q35609928 | Ischemic preconditioning protects neurons from damage and maintains the immunoreactivity of kynurenic acid in the gerbil hippocampal CA1 region following transient cerebral ischemia |
| Q42433595 | KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion |
| Q35985369 | Ketogenic diet increases concentrations of kynurenic acid in discrete brain structures of young and adult rats |
| Q37170524 | Kynurenic Acid in the digestive system-new facts, new challenges. |
| Q48646602 | Kynurenic acid: a new effector of valproate action? |
| Q42790340 | Kynurenine metabolites and migraine: experimental studies and therapeutic perspectives |
| Q37772582 | Kynurenines, neurodegeneration and Alzheimer's disease |
| Q39393210 | Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis. |
| Q51764886 | Mitochondrial oxodicarboxylate carrier deficiency is associated with mitochondrial DNA depletion and spinal muscular atrophy-like disease. |
| Q37844573 | Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. |
| Q41268825 | ONO-2506 inhibits spike-wave discharges in a genetic animal model without affecting traditional convulsive tests via gliotransmission regulation. |
| Q37741285 | Pharmacological therapy in Parkinson's disease: focus on neuroprotection |
| Q35831201 | Potato- an important source of nutritional kynurenic acid |
| Q47627884 | Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis |
| Q24602778 | Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior |
| Q38197710 | Safinamide for the treatment of Parkinson's disease. |
| Q27657768 | Structure, expression, and function of kynurenine aminotransferases in human and rodent brains |
| Q30654478 | Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice. |
| Q38253558 | The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia. |
| Q37877065 | The L-kynurenine signalling pathway in trigeminal pain processing: a potential therapeutic target in migraine? |
| Q91971676 | The Opposite Effects of Kynurenic Acid and Different Kynurenic Acid Analogs on Tumor Necrosis Factor-α (TNF-α) Production and Tumor Necrosis Factor-Stimulated Gene-6 (TSG-6) Expression |
| Q38103448 | The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease. |
| Q47820171 | The kynurenine pathway of tryptophan degradation is activated during osteoblastogenesis. |
| Q37977023 | The role of kynurenines in the pathomechanism of amyotrophic lateral sclerosis and multiple sclerosis: therapeutic implications |
| Q42314534 | Topical dura mater application of CFA induces enhanced expression of c-fos and glutamate in rat trigeminal nucleus caudalis: attenuated by KYNA derivate (SZR72). |
| Q28484900 | Xanthurenic acid binds to neuronal G-protein-coupled receptors that secondarily activate cationic channels in the cell line NCB-20 |
Search more.